Silo Pharma, Inc.
SILO
$2.15
-$0.13-5.70%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00% | 0.00% | 0.00% | 0.00% |
| Cost of Revenue | -- | 1,280.00% | 1,280.00% | 1,280.00% | 0.00% |
| Gross Profit | -- | -116.27% | -116.27% | -116.27% | 0.00% |
| SG&A Expenses | 15.08% | 12.00% | -36.63% | 18.88% | -12.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.66% | 45.01% | -56.07% | 13.75% | 24.08% |
| Operating Income | 25.60% | -45.75% | 56.63% | -14.00% | -24.51% |
| Income Before Tax | 30.85% | -59.70% | 49.06% | -19.55% | -29.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.85% | -59.70% | 49.06% | -19.55% | -29.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.85% | -59.70% | 49.06% | -19.55% | -29.24% |
| EBIT | 25.60% | -45.75% | 56.63% | -14.00% | -24.51% |
| EBITDA | 25.69% | -45.89% | 56.71% | -13.83% | -- |
| EPS Basic | 73.65% | 47.76% | 82.90% | 44.89% | 37.17% |
| Normalized Basic EPS | 70.58% | 47.97% | 82.97% | 44.89% | 37.03% |
| EPS Diluted | 73.65% | 47.76% | 82.90% | 44.89% | 37.17% |
| Normalized Diluted EPS | 70.58% | 47.97% | 82.97% | 44.89% | 37.03% |
| Average Basic Shares Outstanding | 162.42% | 205.65% | 197.90% | 116.91% | 105.70% |
| Average Diluted Shares Outstanding | 162.42% | 205.65% | 197.90% | 116.91% | 105.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |